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annual total cost per subject in relation to disease severity (GOLD) was: €783 (mild),
€2,567 (moderate), €6,818 (severe), and €19,927 (very severe). Indirect costs were
higher than direct costs in all severity stages. For direct costs, main cost drivers
were hospitalizations in severe and very severe disease, and drugs in mild and
moderate COPD, respectively. The main cost driver in indirect costs was produc-
tivity loss due to early retirement, except in mild disease where the driver was
sick-leave. In comparison with a similar study performed in 1999 a numerical
increase in mean annual total costs per subject was observed (ns). The total costs of
COPD in 2010 could be estimated to about €1212-1469 million, with indirect costs
accounting for about 70% of the total costs. CONCLUSIONS: The costs of COPD are
still high in Sweden, and the costs increase considerably by disease severity.
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OBJECTIVES:This study aimed to assess the economical impact of the CAP patients
identified through the study period. METHODS: Retrospective review of medical
records of all patients 18 years old diagnosed with CAP from January 1, 2008 to
December 31, 2009 belonging to Badalona (population  18 years: 90,315) and at-
tended by 6 primary care centres and 2 hospitals (68,274 patients seen throughout
the study period, 6 months). Economical analysis (resource utilization and direct/
indirect associated cost) is presented. Statistical analysis was performed through a
regression model and Bonferoni-adjusted ANCOVA; p0.05. RESULTS: Among the
581 patients identified [55.6% males, mean age 57.5 (SD 19,1)], 41.5% (241) were
hospitalized. Total cost per patient was 1365.97€ (85.2% related to health care direct
costs and 14.8% to non-health care costs due to sick leaves). Ambulatory care
accounted for 154.24€ (13.25%) and hospital care 1010.25€ (86.75%) of the direct
costs; p0.001. Greater impact was due to hospitalization length of stay (71.47%),
primary care pharmacological costs (13.24%) and specialist visits (11.42%). CAP
costs were related to age (r0.303); Fine scale score (r0.437) and re-hospitalization
(r0.667); p0.001. Overall cost per patient increased with age (1138€ in patients
65 year-old vs. 1716€ in  65 year-old; p0.001). CONCLUSIONS: CAP is still asso-
ciated with high economic burden in our country which is mainly due to hospital
care cost (almost one out of two patients were hospitalized). New preventive mea-
sures under development could reduce this impact.
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OBJECTIVES: The first official data on COPD prevalence, morbidity and mortality in
Ukraine were introduced in 2009 report of National Center of Medical Statistics
(2010). Nevertheless, there were no information on a number of specialists’ con-
sultations, a number of disability days and hospitalizations’ frequency in Ukrai-
nian COPD patient cohort. METHODS: Real-life 12 previous month’s data from the
personal medical cards (90%) and interview-lists (10%) of II-III severity stage COPD
patients were analyzed retrospectively. The study was conducted in three regional
clinical centers Bila-Tserkva (Kiev region), Ivano-Frankivsk, Lutsk (Volyn’ region).
Costs of COPD were calculated through the analysis of a number of GPs’ and pul-
monologists’ consultations, a number of lost working days due to COPD, and COPD
related hospitalizations frequency during the last 12 months. Direct medical costs
included outpatient costs (specialists’ consultations, control spirometry once a
year) and inpatient costs (diagnostic measures and hospital-service costs), indirect
costs included productivity loss (absenteeism and presenteeism) and disability
compensations. The 2010-2011 medical service inflation (11.45%), salary growth
rate (25%), social tax (18.6%) and Value Added Tax (17%) discounted the calcula-
tions. Exchange rate: 1EUR  11.42UAH on 18.06.2011. RESULTS: The total study
sample contained 132 patients, aged from 24 to 65 (mean age 49.4910.02), males -
60.61 %. The number of GPs’ and Pulmonologists’ consultations per COPD patient
was 2.63 and 1.18 per year respectively. The number of lost working days due to
COPD was 12.63 per patient annually and a frequency of COPD related hospitaliza-
tions was 0.56 per 12 months. The total COPD costs in Ukraine in 2009 were
€38870506 (103.03 per patient) with €28448213 (73.8%) direct medical costs and
€10422293 (26.82%) indirect costs. CONCLUSIONS: The pilot study results showed
that costs per COPD patient in Ukraine are large and could correspond with costs in
several EU countries. Nevertheless, COPD in Ukraine is underdiagnosed and under-
estimated.
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OBJECTIVES: Cystic fibrosis (CF) is an inherited disease that leads to progressive
damage to the respiratory system, the digestive system, and other organs. Medical
care utilization for patients with CF can be substantial. Recent studies of privately
insured patients with CF in the US have been fairly consistent in their estimates of
annual costs for the average or median patient with CF. However, the variation in
cost is considerable and those patients in the tail of the distribution are also those
with the most severe disease. METHODS: A national employer based claims data-
base for the years 2004 to 2008 was used to identify patients with a valid CF diag-
nosis using multiple criteria. There were a total of 5019 unique patients with CF
who had at least 1 year of continuous enrollment in the health plan. Annual all
cause costs were calculated in total and by different settings and type of cost. The
distribution of total costs was examined and the top 2.5 percentile (111 patients)
were identified as high cost users. RESULTS: While the average annual cost was
approximately $50,000 for patients in our data, the average for the high cost users
was over tenfold higher and ranged between $270,000 and $3.1 million. The vast
majority of these costs were for inpatient stays with the average number of days
spent in the hospital of 87 days. CONCLUSIONS: In this study we used a US admin-
istrative claims database to take a closer look at the most resource intensive pa-
tients with CF. A greater understanding of this group can help inform stakeholders
of the level of expenses to be incurred in the treatment of severe illness and aid in
cost-analysis of treatments.
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OBJECTIVES: This study aimed to assess the economical impact of the hospitalized
CAP patients identified through the study period. METHODS: Retrospective review
of medical records of all patients18 years old diagnosed with CAP from January 1,
2008 to December 31, 2009 belonging to Badalona (population  18 years: 90,315)
and attended by 6 primary care centres and 2 hospitals (68,274 patients seen
throughout the study period). Economical analysis of hospitalized CAP (resource
utilization and direct/indirect associated cost) is presented. Statistical analysis was
performed through a regression model and Bonferoni-adjusted ANCOVA; p0.05.
RESULTS: Among the 518 patients diagnosed with CAP included, 241 were hospi-
talized (41.5%), mean age 66.6 (SD 16.4) years-old, 55.6% males. Adjusted mean total
cost per patient was 2,332.4€ (sick leaves: 191.6€ and health care costs: 2,140.8€).
Healthcare cost was mainly caused by hospital length of stay and specialist visits
costs. Likelihood of inpatient admission increased with liver disease (OR5.9),
stroke (OR3.6), dementia (OR3.5), COPD (OR2.9), diabetes mellitus (OR1.9)
and age (OR 1.1); p0.002. Patient suffering from these co-morbidities (except
dementia) had higher hospital related costs: liver disease (2896.6€); stroke (2960.2€),
COPD (2701.9€) and diabetes mellitus (3,057.7€); p0.001. Direct hospital costs per
patient increased with patient age (805€ in patients 65 year-old vs. 1,716€ in  65
year-old; p0.001). Streptococcus pneumoniae was the most prevalent pathogen
identified [82/114 culture-positive inpatients (71.9%)]. Patients with confirmed
pneumococcal pneumonia had greater overall mean cost (2864.7€ vs. 2259.8€;
p0.041) and healthcare cost (2722.1€ vs. 2,153.6€; p0.047) than those
not-confirmed. CONCLUSIONS: CAP caused great hospital resource utilization,
mainly due to hospitalization days. Those patients older and/or suffering from
co-morbidities had greater likelihood for inpatient admission and higher hospital
related costs.
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OBJECTIVES: To review published evidence on the economic and humanistic
(health related quality of life (HRQoL)) burden of dyspnoea in patients with chronic
obstructive pulmonary disease (COPD). METHODS: A systematic literature search
was performed using PubMed and Embase databases. Search terms identified stud-
ies on economic and humanistic burden of dyspnoea in patients with COPD pub-
lished since 2000 in English.RESULTS:Two articles for economic burden and six for
humanistic burden were identified. The economic studies used different method-
ology; one a cohort study and another chart review. Both studies showed that
dyspnoea within COPD is associated with higher costs. Five quantitative and one
qualitative study were identified for humanistic burden. The quantitative studies
concluded there is a correlation between dyspnoea and QoL. Although consider-
able variation was observed around the parameters used to define dyspnoea, in-
cluding forced expiratory volume in one second (FEV1) forced vital capacity (FVC),
baseline dyspnoea index (BDI) and transitional dyspnoea index (TDI) and instru-
ments used to assess QoL, including the World Health Organisation quality of life –
BREF (WHOQOL-BREF), Borg scale and chronic respiratory disease questionnaire
(CRQ). The qualitative study was based on interviews. Patients identified breath-
lessness as the worst COPD symptom, affecting nutritional intake and an associa-
tion with anxiety. Overall, humanistic burden studies showed dyspnoea has a
significant impact on the QoL. The main limitations of the reviewed studies were
variation in instruments used to assess QoL and dyspnoea and small sample size
(range: n10-n130). CONCLUSIONS: Studies identified in this review varied in
methodological approach and were based on relatively small patient populations.
The findings of this review suggest dyspnoea may be an important predictor of
health related quality of life and economic burden in COPD. There are significant
limitations in the current evidence base, further research is required before firmer
conclusions can be drawn.
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